in this issue
Regions :: Western Europe :: Switzerland
Lonza to Expand Cytotoxic API Capacity in Switzerland
May 12, 2011 | Deepti Ramesh
Lonza says it will invest SF24 million ($27 million) to expand cytotoxic manufacturing capabilities at the company’s site at Visp, Switzerland. Cytotoxic active pharmaceutical ingredients (APIs) are widely used in oncology therapeutics, one of the fastest growing segments of the pharma and biotech industries, Lonza says. “This investment speeds our efforts to establish the Lonza Visp site as a center of excellence for high potency manufacturing,” says Stefan Stoffel, head of Lonza’s chemical manufacturing business unit. “With the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be: